Gilead goes for lung delivery of remdesivir, earlier COVID-19 disease stage

As European approval of IV remdesivir fast approaches, Gilead said it will begin evaluating an inhaled formulation of the antiviral drug -- a path that could take it out of the hospital. The move comes as mounting data indicate treatments targeting SARS-CoV-2 are more likely to provide benefit at early rather than late stages of COVID-19.

EMA’s CHMP announced on Thursday its support for conditional approval of an MAA for Veklury remdesivir to treat COVID-19 patients ages 12 and older who have pneumonia and require supplemental oxygen. It’s the agency’s first positive recommendation for a COVID-19 therapy...